Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOSTER evolving study platform with CabOS randomization
2023-505575-69-01Phase 3Authorised
- Sponsor
- Gustave Roussy
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial in osteosarcoma (OS) comparing Cabozantinib maintenance with Best supportive care (2 arms). Primary endpoints: Event-free survival from diagnosis and Event-free survival from randomisation. Planned start Jul 2026; status: authorised.
02
Drugs
cabozantinib
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on 2023-505575-69-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505575-69-01.